In Vivo Model Development for Kidney Fibrosis

Ace Therapeutics offers a comprehensive in vivo animal model development service tailored for the study and evaluation of kidney fibrosis. Leveraging our deep expertise in preclinical modeling, we provide a diverse portfolio of scientifically validated murine and rat models that enable robust assessment of anti-fibrotic therapies, novel drug candidates, and mechanistic pathways in renal fibrosis.

Kidney fibrosis is a progressive pathological process underlying chronic kidney disease (CKD) and end-stage renal failure, conditions with significant unmet clinical need. Animal models are indispensable for unraveling the molecular mechanisms of fibrosis, identifying therapeutic targets, and evaluating the efficacy and safety of candidate interventions. Ace Therapeutics utilizes a wide spectrum of mouse (Mus musculus) and rat (Rattus norvegicus) strains—including C57BL/6, Balb/c, CD-1, Sv129, SHR, Sprague Dawley, and Wistar—each selected for their genetic backgrounds, susceptibility to fibrosis, and translational relevance to human disease. Our models recapitulate key features of human renal fibrosis, such as extracellular matrix deposition, tubular atrophy, and functional decline, ensuring high predictive value for clinical outcomes.

Chemically-Induced Models

Chemically-induced kidney fibrosis models involve the administration of nephrotoxic agents such as doxorubicin hydrochloride, folic acid, or streptozocin to provoke acute or chronic renal injury, leading to fibrotic remodeling. Methodologies typically include intraperitoneal or intravenous injection of the agent, followed by longitudinal monitoring of kidney function and histopathology. Key advantages include rapid induction, dose-dependent severity, and reproducibility. These models are ideal for screening anti-fibrotic compounds, studying mechanisms of toxin-induced injury, and evaluating renoprotective strategies.

Surgical Models (Obstruction and Ischemia/Reperfusion)

Surgical models, such as unilateral ureteric obstruction (UUO), ureteric ligation, and ischemia/reperfusion (I/R) injury, simulate mechanical or vascular insults that result in progressive interstitial fibrosis. Techniques involve ligating the ureter or temporarily clamping the renal artery to induce injury. These models offer precise temporal and spatial control over injury induction, and closely mimic clinical scenarios like obstructive nephropathy or acute kidney injury. They are extensively used to investigate molecular pathways, test therapeutic interventions, and study the progression and resolution of fibrosis.

Genetic and Transgenic Models

Genetic and transgenic models utilize mice or rats with targeted gene knockouts (e.g., Col4a3, Ppargc1a, Trpc6) or mutations (e.g., Rasal1), as well as transgenic overexpression (e.g., Col1a1), to study the contribution of specific genes to renal fibrosis. These models are generated via advanced genome editing techniques or selective breeding. Their primary advantage lies in elucidating gene function, dissecting signaling pathways, and modeling hereditary forms of kidney fibrosis, providing invaluable insights for precision medicine approaches.

Dietary and Biological Agent-Induced Models

Dietary models, such as high-salt diet in SHR rats, and biological agent-induced models (e.g., administration of specific peptides or proteins), create fibrotic phenotypes through environmental or systemic triggers. These approaches are valuable for modeling metabolic and hypertensive contributors to fibrosis, as well as for studying systemic interactions and comorbidities. They enable researchers to evaluate interventions in the context of complex, multifactorial disease states.

Subtotal Nephrectomy Models

Subtotal nephrectomy models involve surgical removal of a significant portion (e.g., 5/6) of renal mass, resulting in compensatory hypertrophy and progressive fibrosis in the remaining tissue. This method is widely used to model chronic kidney disease and its sequelae, allowing for long-term studies of disease progression, hemodynamic changes, and therapeutic efficacy.

Ace Therapeutics delivers a full-spectrum solution for in vivo kidney fibrosis research, encompassing model selection, study design, surgical and chemical induction, animal care, and comprehensive endpoint analysis. Key efficacy endpoints include renal function assessment (serum creatinine, BUN), histological scoring (fibrosis area, collagen deposition via Masson's trichrome or Sirius Red staining), molecular profiling (qPCR, Western blot for fibrosis markers), and imaging (ultrasound, MRI). Our analytical capabilities extend to immunohistochemistry, transcriptomics, and biomarker quantification. Rigorous quality control is maintained through standardized protocols, experienced surgical teams, and validated readouts, ensuring reproducibility and translational relevance.

Partnering with Ace Therapeutics provides researchers with access to a robust, versatile platform for preclinical kidney fibrosis studies, backed by scientific rigor and customized support. Our integrated approach accelerates the discovery and validation of novel therapeutics, reduces translational risk, and delivers actionable data to advance your research objectives. Contact us today to discuss your project needs and experience the Ace Therapeutics difference.